4 products found
BRIM Biotechnology, Inc. Products
-
BRIM Biotechnology - Model BRM421 - Drug for Dry Eye Syndrome
Our lead asset, BRM421, is on track to become a first-in-class treatment for Dry Eye Syndrome (DES) which treats and repairs corneal damage. BRIM Biotechnology is accelerating the cycle of innovation by leveraging its PDSP technology platform to bring novel ophthalmology treatments to ...
-
BRIM Biotechnology - Model BRM423 - Drug for Severe Cornea Damage
BRM423 is targeted to treat severe corneal damage. BRM423 is novel synthetic peptide derived from human Pigment Epithelium-Derived Factor (PEDF). Its active ingredient is the same as the BRM421 for Dry Eye Syndrome, but it is targeted to treat severe corneal damage. Based on BRIM’s proprietary PDSP technology platform, BRIM intends to rapidly advance development of this novel treatment for corneal damage ...
-
BRIM Biotechnology - Model BRM 424 - Neurotrophic Keratitis (NK)
Neurotrophic Keratitis is a rare, degenerative disease characterised by corneal sensitivity reduction, spontaneous epithelium breakdown, and impairment of corneal healing. Currently, there is only one drug, Oxervate (Cenegermin), approved by the US FDA and EMA in 2018. Eye health is crucial to quality of life and BRIM is advancing new therapeutics to support patients affected by Neurotrophic ...
-
BRIM Biotechnology - Model BRM521 - Novel Drugs for Osteoarthritis
Novel drugs to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology is developing novel drugs to relieve and repair tissue damage caused by osteoarthritis. BRM521’s unique mechanism of action promotes joint cartilage regeneration and relieves ...